We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Gilead Sciences today announced that the company has entered into a licensing
agreement with Japan Tobacco, under which JT has granted to Gilead exclusive
rights to develop and commercialize a novel HIV integrase inhibitor (JTK-303)
in all countries of the world, excluding Japan, where JT will retain rights.
Prime Minister John Howard has pledged to consider the bottom line for pharmacists
when negotiating a new deal over the cost of medicines, but he wants to ensure
there is no blowout in the federal Budget.
Africa risks missing out on the rewards of a revolution in genetic science unless
it can win a bigger slice of funding for diseases like AIDS and malaria, according
to researchers meeting in Kenya on Monday.
AXM Pharma announced today that it has signed a 2005 Distribution Agreement
for 3,000,000 RMB (US$362,757) with Wuhan Jianda Commercial Trade Co. LTD. for
the Company's line of Whisper feminine hygiene products and Anti-fatigue capsules
for distribution in Hubei province.
Cobalis Corp., a pharmaceutical company specializing
in the development of anti-allergy medications, announced that the Company has
signed a comprehensive marketing consulting agreement with Sydney, Australia-based
Trendtrade International Pty. to be the Company's representative/partner for
Australian marketing.
Brazilian health regulatory agency Anvisa has announced that it has
sent documentation to pharmacies, issuing guidance on a controversial new law
allowing dispensers to split drug packets into new boxes.
New patent legislation to comply with India's WTO obligations is
at last under discussion in the country's legislature, but the bill has continued
to attract strong criticism from NGOs and leftist parties.
Sequoia Pharmaceuticals, Inc., a company focused on discovering novel drugs
to combat drug-resistant viral infections, announced that it closed on a $22
million Series B round of financing.